AEZS Company Financial Information

Symbol Info
Aeterna Zentaris Inc. (AEZS)
Listed Symbol	AEZS
Name	Aeterna Zentaris Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share	$-
Latest Fiscal Date	2018-12-31
Latest Fiscal Revenue	$26,881,000
Latest Fiscal EPS	$0.25
Price Info
21 Day Moving Average	$1.0253
21 Day EMA	$1.107790
50 Day Moving Average	$1.5973
50 Day EMA	$1.516830
200 Day EMA	$2.429420
200 Day Moving Average	3.025530
52 Week High	$5.57
52 Week Low	$0.81
52 Week Change	$-23.021599
Alpha	-0.032256
Beta	1.1109
Standard Deviation	0.322988
R2	0.013953
Periods	60
Share Information
10 Day Average Volume	180,515
20 Day Average Volume	217,032
30 Day Average Volume	212,745
50 Day Average Volume	166,327
Outstanding Shares	19,882,410
Float Shares	19,882,410
Percent Float	100.00%
Short Interest	-
Short Percent Float	-
Short Interest Ratio	-
Short Date
Holders
Institutions	48
Institute Holdings Date	2019-09-30
Institute Bought Previous 3 Months	27,870
Institute Holdings Percent	8.100000
Institute Sold Previous 3 Months	453,799
Insider Holdings Date
Insider Bought Previous 3 Months	-
Insider Holdings Percent	-
Insider Sold Previous 3 Months	-
Insiders Shares Owned	-
Price Change
7 Day Price Change	$0.1676000
7 Day Percent Change	18.57%
21 Day Price Change	$0.0740001
21 Day Percent Change	7.43%
30 Day Price Change	$-0.5647999
30 Day Percent Change	-34.55%
Month To Date Price Change	$0.0400
Month To Date Percent	3.88%
90 Day Price Change	$-1.47
90 Day Percent Change	-57.87%
Quarter To Date	$0.040000
Quarter To Date Percent	3.88%
180 Day Price Change	$-3.18
180 Day Percent Change	-74.82%
200 Day Price Change	$-4.03
200 Day Percent Change	-79.02%
Year To Date	$-1.87
Year To Date Percent	-63.61%
Profile
Description	AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. The company focuses on the acquisition of licenses to products that are relevant to their therapeutic areas of focus. Its primary product is Apifiny. It is developing Macrilen, Zoptrex and AEZS drugs in the pipeline.
Details
Issue Type	CS
Market Cap	$21,274,179
Sec Type	EQS
Auditor	PricewaterhouseCoopers LLP
Total Shares Outstanding	19,954,290
CEO	Michael Ward
Employees	22
Last Audit	UQ
Classification
CIK	0001113423
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)
Info
Address	315 Sigma Drive Suite 302D Summerville, SC 29486
Website	https://www.zentaris.com
Facisimile
Telephone	+1 843 900-3201
Email	IR@aezsinc.com
Key Ratios
Profitability
EBIT Margin	-497.8
EBITDA Margin	-490.9
Pre-Tax Profit Margin	-33,870.6
Profit Margin Cont	-
Gross Margin	12.20
Profit Margin TOT	-
Income Statements
Revenue	$1,623,000
Revenue Per Share	$0.1929
Revenue 3 Years	$121.93
Revenue 5 Years	$-
Valuation Measures
PE Ratio	-
Enterprise Value	$12,323,388
Price To Sales	5.545801
Price To Free Cash	-2.7
PE High Last 5 Years	-
Price To Book	34.1
Price To Cash Flow	9.9
PE Low Last 5 Years	-
Price To Tangible Book	-1.8
Financial Strength
Total Debt To Equity	-
Int Coverage	-
Current Ratio	1.7
Leverage Ratio	-3.3
Quick Ratio	1.4
Long Term Debt To Capital	-
Assets
Receivables Turnover	1.6
Invoice Turnover	1.90
Assets Turnover	-
Management Effectiveness
Return Assets	-47.11
Return On Equity	-380.75
Return On Capital	-280.46
Dividends
Dividend 3 Years	$-
Dividend 5 Years	$-
Ex Dividend Date
Dividend Rate	$-
Dividend Yield	-
Payment Type